Pathos
Chicago, US · Founded 2020 · 3 known investors
Find your way into Pathos
391 people in our graph share verified history with the Pathos team — schools, employers, funds. One of them is your warm intro.
Mike Zakunlockedknows Matthew De Silva · together at Cornell (overlapped)
knows the team · via Cornell
knows the team · via Bank of America Merrill Lynch
knows the team · via Tempus AI
knows the team · via Pathos
knows the team · via Purdue University Daniels School of Business
Pathos applies AI, biological modeling, and a large collection of multimodal oncology patient data to develop cancer drugs and accelerate clinical development. It operates the PathOS platform with engines for asset selection, clinical trial execution, and an oncology foundation model.
Founders & leadership
Pathos was founded in 2020 by Eric Lefkofky, Eric Lefkofsky, and Ryan Fukushima.
EL
Eric LefkofkyCo-founder
EL
Eric LefkofskyCo-founder
RF
Ryan FukushimainCo-founderRyan Fukushima was the first employee at Tempus AI and held leadership roles through its IPO, and currently serves as cofounder and CEO of Pathos, an AI-driven drug development platform focused on oncology therapeutics.
AH
Andrew HeinleinExecutive
AD
Alex DolaninGeneral Counsel
IH
Iker HuergainChief Executive Officer and Board Member
ES
Eric SchadtinChief Science Officer
MD
Board
AM
Amit MehtaBoard director
MM
Investors · 3
Reported raises · per SEC filings
Form D private placements$365M disclosed across 3 rounds · 2023–2025
▶$283MraisedMay 2025 · 11 investors · BiotechnologyRule 506(b)
▶$283MraisedMay 2025 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ryan FukushimaExecutive Officer, Director
- Mohamad MakhzoumiDirector
- Alex DolanExecutive Officer
- Andrew HeinleinExecutive Officer
- Tyrell RiversDirector
- Amit MehtaDirector
- Eric LefkofkyExecutive Officer, Director
- Offering amount
- $400M
- Amount sold
- $283M
- First sale
- Apr 2025
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$62MraisedNov 2024 · 13 investors · BiotechnologyRule 506(b)
▶$62MraisedNov 2024 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Eric LefkofkyExecutive Officer, Director
- Amit MehtaDirector
- Ryan FukushimaExecutive Officer, Director
- Andrew HeinleinExecutive Officer
- Mohamad MakhzoumiDirector
- Alex DolanExecutive Officer
- Offering amount
- $62M
- Amount sold
- $62M
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$20MraisedMar 2023 · 4 investors · BiotechnologyRule 506(b)
▶$20MraisedMar 2023 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ryan FukushimaExecutive Officer, Director
- Eric LefkofskyExecutive Officer, Director
- Offering amount
- $40M
- Amount sold
- $20M
- First sale
- Feb 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through Pathos went on to found or lead other companies.
In the news
Frequently asked questions
- What does Pathos do?
- Pathos applies AI, biological modeling, and a large collection of multimodal oncology patient data to develop cancer drugs and accelerate clinical development. It operates the PathOS platform with engines for asset selection, clinical trial execution, and an oncology foundation model.
- Who founded Pathos?
- Pathos was founded by Eric Lefkofky, Eric Lefkofsky, Ryan Fukushima in 2020.
- Who are Pathos's investors?
- Pathos's investors include Cota Capital, Lightbank, New Enterprise Associates (NEA).
- How much funding has Pathos raised?
- Pathos has disclosed $365M raised across 3 rounds.
- Where is Pathos headquartered?
- Pathos is headquartered in Chicago, US.